Measuring the impact of dexrazoxane cardioprotection.
Freyer
David R
DR
D009202:Cardiomyopathies / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D004317:Doxorubicin / Q000009:adverse effects; D004341:Drug Evaluation; D025401:Echocardiography, Stress; D006801:Humans; D011929:Razoxane / Q000627:therapeutic use*; D012189:Retrospective Studies; D012306:Risk
D002316:Cardiotonic Agents; D011929:Razoxane; D004317:Doxorubicin